Table 3.
Short-term lipid profile alteration among statin plus ezetimibe plus evolocumab/statin/statin plus ezetimibe lipid-lowering strategies in AMI patients after PSM adjustment
| Statin | Statin +Ezetimibe |
Statin + Ezetimibe + Evolocumab | p1 | p2 | ||
|---|---|---|---|---|---|---|
| LDL (mmol/L) | Admission | 3.59 ± 0.95 | 3.82 ± 1.20 | 3.90 ± 1.45 | 0.060 | 0.666 |
| Follow-up(1 m) | 1.96 ± 0.49 | 2.04 ± 0.81 | 1.43 ± 1.06 | 0.001 | 0.001 | |
| Follow-up(3 m) | 2.06 ± 0.42 | 2.37 ± 1.13 | 1.40 ± 0.50 | < 0.001 | < 0.001 | |
| TG (mmol/L) | Admission | 2.08 ± 1.12 | 1.92 ± 1.04 | 1.93 ± 1.01 | 0.311 | 0.948 |
| Follow-up(1 m) | 1.72 ± 0.71 | 1.58 ± 0.68 | 1.50 ± 0.72 | 0.148 | 0.539 | |
| Follow-up(3 m) | 1.53 ± 0.64 | 1.82 ± 0.74 | 1.74 ± 1.17 | 0.534 | 0.796 | |
| HDL (mmol/L) | Admission | 0.98 ± 0.24 | 1.01 ± 0.22 | 1.00 ± 0.23 | 0.472 | 0.818 |
| Follow-up(1 m) | 0.99 ± 0.24 | 0.99 ± 0.21 | 0.94 ± 0.21 | 0.253 | 0.176 | |
| Follow-up(3 m) | 1.03 ± 0.29 | 1.00 ± 0.27 | 0.95 ± 0.18 | 0.316 | 0.491 | |
| ApoA (g/L) | Admission | 1.09 ± 0.19 | 1.11 ± 0.20 | 1.09 ± 0.21 | 0.877 | 0.456 |
| Follow-up(1 m) | 1.15 ± 0.20 | 1.14 ± 0.19 | 1.10 ± 0.18 | 0.850 | 0.336 | |
| Follow-up(3 m) | 1.11 ± 0.16 | 1.15 ± 0.23 | 1.12 ± 0.14 | 0.525 | 0.606 | |
| ApoB (g/L) | Admission | 1.16 ± 0.29 | 1.15 ± 0.24 | 1.16 ± 0.29 | 0.269 | 0.730 |
| Follow-up(1 m) | 0.75 ± 0.17 | 0.76 ± 0.20 | 0.59 ± 0.29 | 0.004 | 0.001 | |
| Follow-up(3 m) | 0.80 ± 0.13 | 0.83 ± 0.29 | 0.61 ± 0.20 | 0.008 | 0.010 | |
| ApoE (mg/L) | Admission | 46.68 ± 19.88 | 46.90 ± 21.08 | 46.68 ± 19.88 | 0.825 | 0.939 |
| Follow-up(1 m) | 31.00 ± 8.62 | 36.77 ± 16.37 | 28.92 ± 13.96 | 0.573 | 0.061 | |
| Follow-up(3 m) | 37.91 ± 10.10 | 34.56 ± 14.43 | 30.26 ± 14.06 | 0.265 | 0.466 | |
| LP(a) (mg/L) | Admission | 331.77 | 375.71 | 433.87 | 0.982 | 0.248 |
| Follow-up(1 m) | 450.00 | 283.66 | 271.18 | 0.587 | 0.851 | |
| Follow-up(3 m) | 435.08 | 427.27 | 595.43 | 0.502 | 0.332 | |
| TCDL (mmol/L) | Admission | 5.55 ± 1.14 | 5.72 ± 1.30 | 5.79 ± 1.42 | 0.181 | 0.739 |
| Follow-up(1 m) | 3.52 ± 0.65 | 3.55 ± 0.89 | 2.82 ± 1.18 | < 0.001 | < 0.001 | |
| Follow-up(3 m) | 3.65 ± 0.74 | 3.93 ± 1.39 | 2.97 ± 0.64 | 0.009 | 0.003 | |
Data are shown as the mean ± SD, median or n (%). p1, Statin plus ezetimibe plus evolocumab vs. statin; p2, Statin plus ezetimibe plus evolocumab vs. statin plus ezetimibe. For statistical analysis, one-way ANOVA followed by Sidak’s multiple comparison test was applied
TG Triglyceride, LDL Low-density lipoprotein, HDL High-density lipoprotein, ApoA apolipoprotein A, ApoB Apolipoprotein B, ApoE Apolipoprotein E, TCDL Total cholesterol lipoprotein, Lp(a) Lipoprotein(a)